{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:38:59Z","timestamp":1787164739596,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002352","name":"Ain Shams University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hearing deficit is one of the side effects of 1st generation iron chelators in \u03b2-thalassemia, however the risk of hearing deficits following 2nd generation iron chelators is not well known.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To assess hearing status of Transfusion Dependent \u03b2-thalassemia children on oral iron chelating agents and detect risk factors for hearing impairment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a cross-sectional study recruited sixty children and adolescent with confirmed diagnosis of transfusion dependent \u03b2-thalassemia. Demographic and clinical characteristics collected, audiological testing were performed by the same audiologist using the same equipment for all patients including tympanometry, pure tone audiometry, speech audiometry, transient evoked otoacoustic emissions and distortion product otoacoustic emissions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Recruited children and adolescents with transfusion dependent \u03b2-thalassemia were 32 (53.3%) boys and 28 (46.7%) girls and their mean age was 11.34\u2009\u00b1\u20093.08, majority of patients 48 (80%) were on single Deferasirox. Our study revealed that among the 60 children evaluated, 16.6% exhibited some form of hearing loss. Sensorineural hearing loss (SNHL) was observed in 6.6% of the participants, while 10% had conductive hearing loss (CHL). Bilateral SNHL in 5% and bilateral CHL in 8.3% of all the cases. Hearing impairment was mild in nature, but predominantly affected high-frequency ranges, the most affected frequencies being 4000\u00a0Hz and 8000\u00a0Hz. There was no significant difference between studied thalassemia children with and without hearing impairment regarding gender, age at study entry, age at diagnosis, duration of disease and duration or dose of chelating agent (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05). Our study revealed significant difference between studied thalassemia children with and without hearing impairment regarding age of starting blood transfusion (\n                      <jats:italic>p<\/jats:italic>\n                      -value\u2009=\u20090.024), affected patients started blood transfusion at older age, also statistically significant difference in both groups regarding median serum ferritin was found (\n                      <jats:italic>p<\/jats:italic>\n                      -value\u2009=\u20090.028), lower levels were found in affected patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>No significant effect of using oral iron chelation drugs was observed on frequency and type of hearing loss among the studied patients but instead the age at starting regular blood transfusion did. Screening of such group of patients for hearing impairment at diagnosis and at regular periods is recommended.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12887-025-06116-3","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:49:23Z","timestamp":1759463363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hearing assessment in transfusion dependent beta-thalassemia children on oral iron chelating agent"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5174-3398","authenticated-orcid":false,"given":"Wafaa E. I.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1723-9785","authenticated-orcid":false,"given":"Marwa Waheed","family":"Tolba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara Khalid","family":"Abuelfadl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4929-1156","authenticated-orcid":false,"given":"Abeer","family":"Mohamed Elgendy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5763-3541","authenticated-orcid":false,"given":"Heba G. A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"6116_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-7299-9_1","volume":"1013","author":"PT McGann","year":"2017","unstructured":"McGann PT, Nero AC, Ware RE. Clinical features of thalassemia and sickle cell disease. Adv Exp Med Biol. 2017;1013:1\u201326.","journal-title":"Adv Exp Med Biol"},{"key":"6116_CR2","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/gim.2016.173","volume":"19","author":"R Origa","year":"2017","unstructured":"Origa R. Thalassemia. Genet Med. 2017;19:609\u201319.","journal-title":"Genet Med"},{"issue":"1","key":"6116_CR3","doi-asserted-by":"publisher","first-page":"e05","DOI":"10.34172\/npj.2021.05","volume":"10","author":"B Keikhaei","year":"2020","unstructured":"Keikhaei B, Farmani-Anooshe N, Bahadoram M, Mahmoudian-Sani MR, Alikhani K, Helalinasab A. An overview of complications associated with deferoxamine therapy in thalassemia. J Nephropharmacol. 2020;10(1):e05.","journal-title":"J Nephropharmacol"},{"issue":"1","key":"6116_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11010102","volume":"11","author":"I Tartaglione","year":"2021","unstructured":"Tartaglione I, Carfora R, Brotto D, Barillari MR, Costa G, Perrotta S, et al. Hearing loss in Beta-Thalassemia: systematic review. J Clin Med. 2021;11(1):102.","journal-title":"J Clin Med"},{"issue":"1","key":"6116_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-021-01969-0","volume":"16","author":"R Manara","year":"2021","unstructured":"Manara R, Ponticorvo S, Perrotta S, Barillari MR, Costa G, Brotto D, et al. Auditory cortex hypoperfusion: a metabolic hallmark in Beta Thalassemia. Orphanet J Rare Dis. 2021;16(1):1\u20131.","journal-title":"Orphanet J Rare Dis"},{"key":"6116_CR6","first-page":"239","volume":"8","author":"G Badfar","year":"2017","unstructured":"Badfar G, Mansouri A, Shohan M, Karimi H, Khalighi Z, Rahmati, et al. Hearing loss in iranian thalassemia major patients treated with deferoxamine: a systematic review and meta-analysis. Casp J Intern Med. 2017;8:239\u201349.","journal-title":"Casp J Intern Med."},{"issue":"9","key":"6116_CR7","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1182\/blood-2005-08-3430","volume":"107","author":"MD Cappellini","year":"2006","unstructured":"Cappellini MD, Cohen A, Piga A. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with b-thalassemia. Blood. 2006;107(9):3455\u201362.","journal-title":"Blood"},{"issue":"9","key":"6116_CR8","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.leukres.2010.03.009","volume":"34","author":"N Gattermann","year":"2010","unstructured":"Gattermann N, Finelli C, Della Porta M, EPIC Study Investigators. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res. 2010;34(9):1143\u201350.","journal-title":"Leuk Res"},{"issue":"1","key":"6116_CR9","doi-asserted-by":"publisher","first-page":"136","DOI":"10.5152\/iao.2016.1852","volume":"13","author":"S Derin","year":"2017","unstructured":"Derin S, Az\u0131k FM, Topal Y. The incidence of ototoxicity in patients using iron chelators. J Int Adv Otol. 2017;13(1):136.","journal-title":"J Int Adv Otol"},{"issue":"8","key":"6116_CR10","first-page":"e5465","volume":"11","author":"MA Khan","year":"2019","unstructured":"Khan MA, Khan MA, Seedat AM. Sensorineural hearing loss and its relationship with duration of chelation among major b-thalassemia patients. Cureus. 2019;11(8):e5465.","journal-title":"Cureus"},{"key":"6116_CR11","first-page":"102","volume":"11","author":"T Immacolata","year":"2022","unstructured":"Immacolata T, Roberta C, Davide B, Maria R, Giuseppe C, Silverio P, et al. Hearing loss in beta-thalassemia: systematic review. J Clin Med. 2022;11:102.","journal-title":"J Clin Med"},{"key":"6116_CR12","doi-asserted-by":"publisher","unstructured":"American Academy of Family Physicians; American Academy of Otolaryngology-Head and Neck Surgery, American Academy of Pediatrics Subcommittee on Otitis Media With Effusion. Otitis media with effusion. Pediatrics. 2004;113(5):1412-29. https:\/\/doi.org\/10.1542\/peds.113.5.1412. PMID: 15121966.","DOI":"10.1542\/peds.113.5.1412"},{"key":"6116_CR13","first-page":"262","volume":"7","author":"A Goodman","year":"1965","unstructured":"Goodman A. Reference zero levels for pure tone audiometer. Am Speech Hear Assoc. 1965;7:262\u20133.","journal-title":"Am Speech Hear Assoc"},{"key":"6116_CR14","first-page":"27","volume":"27","author":"S Soliman","year":"1976","unstructured":"Soliman S. Speech discrimination audiometry using Arabic phonetically balanced words. Ain Shams Med J. 1976;27:27\u201330.","journal-title":"Ain Shams Med J"},{"key":"6116_CR15","volume-title":"Otoacoustic emissions: principles, procedures, and protocols","author":"S Dhar","year":"2011","unstructured":"Dhar S, Hall JW. Otoacoustic emissions: principles, procedures, and protocols. San Diego, CA: Plural Publishing; 2011."},{"issue":"12","key":"6116_CR16","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1177\/014556131509401206","volume":"94","author":"U Osma","year":"2015","unstructured":"Osma U, Kurtoglu E, Eyigor H, Yilmaz MD, Aygener N. Sensorineural hearing loss in \u03b2-thalassemia patients treatedwith iron chelation. Ear Nose Throat J. 2015;94(12):481\u20135.","journal-title":"Ear Nose Throat J"},{"key":"6116_CR17","doi-asserted-by":"publisher","unstructured":"Tiwana BS, Aggarwal A, Bhagat S, Singh H, Sahni D, Yadav V. Assessing the auditory effects of oral chelation therapy drug Deferasirox in individuals with \u03b2-thalassemia major. World J Otorhinolaryngol Head Neck Surg. 2023;10(4):309-14. https:\/\/doi.org\/10.1002\/wjo2.150. PMID: 39677049; PMCID: PMC11634694 .","DOI":"10.1002\/wjo2.150"},{"issue":"2","key":"6116_CR18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.anl.2023.10.005","volume":"51","author":"M Ald\u00e8","year":"2024","unstructured":"Ald\u00e8 M, Ambrosetti U, Giuditta M, Cassinerio E, Piatti G. Effects on hearing after long-term use of iron chelators in beta-thalassemia: over twenty years of longitudinal follow-up. Auris Nasus Larynx. 2024;51(2):271\u20135.","journal-title":"Auris Nasus Larynx"},{"key":"6116_CR19","first-page":"9","volume":"79","author":"MH Kong","year":"2014","unstructured":"Kong MH, Goh BS, Hamidah A, Zarina AL. The prevalence of sensorineural hearing loss in beta-thalassemia patients treated with desferrioxamine. Med J Malaysia. 2014;79:9\u201312.","journal-title":"Med J Malaysia"},{"key":"6116_CR20","doi-asserted-by":"publisher","first-page":"111868","DOI":"10.1016\/j.ijporl.2024.111868","volume":"177","author":"DH Galhom","year":"2024","unstructured":"Galhom DH, Talaat RM, Hanna D, Gad NH. Audiologic and vestibular assessment in children and adolescents with transfusion dependent beta thalassemia major: the era of deferasirox film coated tablet. Int J Pediatr Otorhinolaryngol. 2024;177:111868.","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"4","key":"6116_CR21","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/bjh.15959","volume":"186","author":"I Tartaglione","year":"2019","unstructured":"Tartaglione I, Manara R, Caiazza M, Carafa PA, Caserta V, Ferrantino T, et al. Brain functional impairment in beta-thalassaemia: the cognitive profile in Italian neurologically asymptomatic adult patients in comparison to the reported literature. Br J Haematol. 2019;186(4):592\u2013607.","journal-title":"Br J Haematol"},{"issue":"4","key":"6116_CR22","first-page":"731","volume":"19","author":"GD Khavidaki","year":"2024","unstructured":"Khavidaki GD, Gharibi R, Naderi M, Sedaghatkia H. The investigation of hearing loss in patients with thalassemia major referred to Hazrat Ali Asghar (AS) Hospital in Sistan and Baluchistan Province (Iran). Maedica (Bucur). 2024;19(4):731\u20135.","journal-title":"Maedica (Bucur)"},{"key":"6116_CR23","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13104-019-4323-z","volume":"12","author":"SH Mohammed","year":"2019","unstructured":"Mohammed SH, Shab-Bidar S, Abuzerr S, Habtewold TD, Alizadeh S, Djafarian K. Association of anemia with sensorineural hearing loss: a systematic review and meta-analysis. BMC Res Notes. 2019;12:283.","journal-title":"BMC Res Notes"},{"issue":"6","key":"6116_CR24","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/08880010802234911","volume":"25","author":"BS Shamsian","year":"2008","unstructured":"Shamsian BS, Aminasnafi A, Moghadassian H, Gachkar L, Arzanian MT, Alavi, et al. Sensory neural hearing loss in \u03b2-thalassemia major patients treated with deferoxamine. Pediatr Hematol Oncol. 2008;25(6):502\u20138.","journal-title":"Pediatr Hematol Oncol."},{"key":"6116_CR25","first-page":"210","volume-title":"An Evaluation of sensory neural hearing loss in thalassaemic patients treated with desferrioxamine and its risk factors","author":"M Sonbolestan","year":"2005","unstructured":"Sonbolestan M, Mokhtarinezhad F, Omrani M. An Evaluation of sensory neural hearing loss in thalassaemic patients treated with desferrioxamine and its risk factors. 2005. p. 210\u20136."},{"issue":"2","key":"6116_CR26","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.anl.2007.05.001","volume":"35","author":"E Delehaye","year":"2008","unstructured":"Delehaye E, Capobianco S, Bertetto IB, Meloni F. Distortion-product otoacoustic emission: early detection in deferoxamine induced ototoxicity. Auris Nasus Larynx. 2008;35(2):198\u2013202.","journal-title":"Auris Nasus Larynx"},{"key":"6116_CR27","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2141.1989.tb07761.x","volume":"73","author":"JB Porter","year":"1989","unstructured":"Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol. 1989;73:403\u20139.","journal-title":"Br J Haematol"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-06116-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-025-06116-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-025-06116-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:49:26Z","timestamp":1759463366000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-025-06116-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6116"],"URL":"https:\/\/doi.org\/10.1186\/s12887-025-06116-3","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"30 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted after approval of the Ethical Committee at Ain Shams University, Faculty of Medicine, under acceptance number FMASU MS\/489\/2023. Informed consent and assent whenever applicable were obtained from each patient and control or their legal guardians before enrolment in the study. All procedures performed were in accordance with the ethical standards of the institutional research board in accordance with Helsinki declaration 2013.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"752"}}